Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-100LI confirmatory study in vocal fold scar
jRCT2051220132Active, not recruiting
- Sponsor
- Kringle Pharma, Inc.
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in scarred vocal fold and Sulcus Vocalis (SV) comparing KP-100LI with Placebo (2 arms). Primary endpoint: Improvement rate in Voice Handicap Index-10 score at week 24. Started Jan 2023; status: active, not recruiting.
02
Drugs
KP-100
03
Conditions
scarred vocal foldSulcus Vocalis (SV)
Beyond the preview
Go deeper on jRCT2051220132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220132.